SNY
Sanofi
Nasdaq: SNY · Paris, I0 · Healthcare
$47.13-0.86 (-1.79%)Closed
Market Cap$57.47B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$43.60 – $53.09
Avg Volume3.0M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$47.13+8.8%
Pipeline

Drug candidates sponsored by Sanofi · ClinicalTrials.gov

90 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Risedronate (HMR4003)
Osteoporosis, Postmenopausal
Completed
2004-06past
1
Phase 4oxaliplatin
Colonic Neoplasms
Completed
2005-06past
1
Phase 4Valproic acid, sodium salt
Bipolar Disorder
Completed
2006-10past
1
Phase 4Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac
Diphtheria+4 more
Completed
2007-09past
1
Phase 4DTacP-IPV combined vaccine (TETRAXIM™)
Diphtheria+3 more
Completed
2010-09past
1
Phase 4Risedronate sodium
Colles' Fracture
Completed
2011-09past
1
Phase 4Insulin glargine
Type 2 Diabetes Mellitus+2 more
Completed
2012-06past
3
Phase 4Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Cholera
Completed
2015-02past
1
Phase 4CABAZITAXEL (XRP6258)
Prostate Cancer+2 more
Completed
2015-07past
3
Phase 4cabazitaxel XRP6258
Prostate Cancer Metastatic+1 more
Completed
2019-03-27past
2
Phase 4alglucosidase alfa
Pompe Disease+2 more
Completed
2021-11-23past
1
Phase 4Insulin glargine/Lixisenatide
Type 2 Diabetes Mellitus
Completed
2023-03-28past
1
Phase 4Nirsevimab
RSV Immunization
Active, not recruiting
2026-06-30
1
Phase 4Irbesartan
Hypertension+1 more
Completed—1
Phase 4Fexofenadine HCl
Cat Induced Allergic Rhinitis
Completed—1
Phase 3zolpidem-MR (modified release)
Sleep Initiation and Maintenance Disorders
Completed
2004-02past
1
Phase 3Rimonabant (SR141716)
Obesity+2 more
Completed
2004-05past
1
Phase 3amibegron (SR58611A)
Major Depressive Disorders
Completed
2004-05past
1
Phase 3SR34006
Pulmonary Embolism
Completed
2005-10past
1
Phase 3Inactivated Poliomyelitis vaccine
Poliomyelitis
Completed
2006-02past
1
Phase 3Zolpidem (SL800750)
Attention Deficit Hyperactivity Disorder
Completed
2006-08past
1
Phase 3Unnamed
Osteoarthritis, Knee+1 more
Completed
2006-09past
1
Phase 3REPEVAX® after REVAXIS®
Healthy Adult
Completed
2007-02past
1
Phase 3xaliproden (SR57746A)
Alzheimer Disease
Completed
2007-10past
1
Phase 3Insulin Glulisine
Diabetes Mellitus, Type 2+1 more
Completed
2007-11past
2
Phase 3Flu-ID 15μg
Influenza
Completed
2007-12past
1
Phase 3saredutant (SR48968)
Depressive Disorder
Completed
2008-02past
1
Phase 3dronedarone (SR33589)
Atrial Fibrillation+1 more
Completed
2008-03past
1
Phase 3Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Meningococcal Meningitis+4 more
Completed
2008-08past
1
Phase 3Eplivanserin
Primary Insomnia
Completed
2009-06past
1
Phase 3Sevelamer carbonate
Chronic Kidney Disease+1 more
Terminated
2009-09past
1
Phase 2Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Head and Neck Neoplasms
Completed
2010-07past
1
Phase 3ZD6474 (Vandetanib)
Thyroid Cancer+1 more
Completed
2010-08past
2
Phase 3LACTIC ACID (Dermacid)
Hygiene
Completed
2010-12past
1
Phase 3Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Carcinoma+1 more
Completed
2011-01past
1
Phase 3Doxorubicine + docetaxel sequential
Breast Neoplasms
Completed
2011-09past
1
Phase 3Insulin human/Insuman Comb 25 (HR1799)
Type 2 Diabetes Mellitus
Completed
2012-11past
1
Phase 3DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide
Diphtheria+4 more
Completed
2013-04past
1
Phase 3Teriflunomide
Multiple Sclerosis Relapse
Terminated
2013-04past
1
Phase 3Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus
Tetanus+4 more
Completed
2013-05past
1
Phase 3oxaliplatin (SR96669)
Hepatic Neoplasm Malignant
Withdrawn
2014-02past
1
Phase 3Quadrivalent Influenza Vaccine (split virion, inactivated)
Influenza
Completed
2014-04past
1
Phase 3Insulin glargine/lixisenatide Fixed Ratio Combination
Type 2 Diabetes
Completed
2015-06past
1
Phase 3SAR342434
Type 1 Diabetes Mellitus
Completed
2015-12past
1
Phase 3Insulin Glargine (HOE901 - U300)
Type 2 Diabetes Mellitus
Completed
2016-05past
1
Phase 3Phosphatidylcholine
Hepatic and Hepatobiliary Disorders
Completed
2016-06past
1
Phase 3Caplacizumab
Acquired Thrombotic Thrombocytopenic Purpura
Completed
2017-08past
1
Phase 3Insulin aspart
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Completed
2018-07-16past
1
Phase 3INSULIN GLARGINE (U300)
Type 2 Diabetes Mellitus
Completed
2018-08-06past
2
Phase 3Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine
Meningococcal Immunisation+1 more
Active, not recruiting
2023-03-09past
1
Phase 3Lunsekimig
Chronic Obstructive Pulmonary Disease
Recruiting
2029-11-27
1
Phase 3Insulin glulisine (HMR1964)
Diabetes, Type I
Completed—1
Phase 2eplivanserin (SR46349)
Fibromyalgia+2 more
Completed
2005-06past
1
Phase 2docetaxel and cisplatin
Head and Neck Neoplasms
Completed
2006-05past
1
Phase 2Nolpitantium besylate
Ulcerative Colitis+1 more
Completed
2006-09past
1
Phase 2Alfuzosin
Acute Urinary Retention
Completed
2007-04past
1
Phase 1Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide
Meningococcal Infections+1 more
Completed
2008-01past
1
Phase 2Vandetanib
Colorectal+1 more
Completed
2008-03past
1
Phase 2SSR180711C
Alzheimer's Disease
Terminated
2008-07past
1
Phase 2docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy
Lung Neoplasms
Completed
2009-02past
1
Phase 2Influenza virus vaccine 2009-2010 formulation
Influenza
Completed
2009-06past
1
Phase 2SAR97276A
Malaria
Terminated
2012-01past
1
Phase 2Semuloparin sodium
Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)
Terminated
2012-07past
1
Phase 2Alirocumab
Hypercholesterolemia
Completed
2013-07past
2
Phase 2SAR100842
Systemic Sclerosis
Completed
2013-11past
1
Phase 2SAR339658
Ulcerative Colitis
Terminated
2014-06past
1
Phase 2teriflunomide (HMR1726)
Multiple Sclerosis
Completed
2015-01past
1
Phase 1SAR245408
Neoplasm Malignant
Completed
2018-05-23past
1
Phase 2Avalglucosidase alfa (GZ402666)
Glycogen Storage Disease Type II-Pompe's Disease
Active, not recruiting
2019-09-30past
1
Phase 2GZ402665
Sphingomyelin Lipidosis
Completed
2023-09-06past
1
Phase 1SAR402663
Neovascular Age-related Macular Degeneration
Recruiting
2027-05-18
1
Phase 1Acne mRNA vaccine
Acne
Recruiting
2029-06-19
1
Phase 1aldesleukin
Melanoma (Skin)
Unknown—1
Phase 2Fetal porcine cells, Neurocell-PD
Parkinson's Disease
Completed—1
Phase 1CLOPIDOGREL
Healthy
Completed
2009-08past
1
Phase 1Insulin glargine HOE901
Type 1 Diabetes Mellitus
Completed
2010-09past
1
Phase 1AVE8062
Advanced Neoplastic Disease
Completed
2011-02past
1
Phase 1Aflibercept (AVE0005)
Neoplasm Malignant
Completed
2011-09past
1
Phase 1SAR231893 (REGN668) DP1
Healthy
Completed
2012-07past
1
Phase 1OMBRABULIN (AVE8062)
Neoplasms
Completed
2013-02past
1
Phase 1sodium valproate
Epilepsy
Completed
2019-04-11past
1
Phase 1Shz QIV 0.25 mL, 2 doses
Influenza+1 more
Completed
2019-06-06past
1
Phase 1DNL747
Amyotrophic Lateral Sclerosis
Terminated
2020-06-18past
1
Phase 1SAR441566
Rheumatoid Arthritis
Completed
2023-07-17past
1
Phase 1mRNA NA vaccine
Influenza Immunization+1 more
Completed
2024-01-03past
1
N/AMyozyme
Glycogen Storage Disease Type II+1 more
Completed
2006-08past
1
N/AAlemtuzumab (MabCampath)
Chronic Lymphocytic Leukemia
Terminated
2009-04past
1
N/AUnnamed
Whooping Cough+1 more
Completed
2018-07-09past
1
N/ADupilumab
Dermatitis Atopic+1 more
Recruiting
2027-05-24
2
N/AUnnamed
Intestinal Obstruction+1 more
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for SNY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.